Biosimilars are eating Rituximab's lunch

added blog Health

2026-04-15 11:54:48 -

Rituximab's patent expired in 2015, and since then, biosimilars have flooded the market. The rituximab market research shows that biosimilars now hold over 70% of the market in some regions, driving prices down. In Europe, a biosimilar Rituximab can cost 50% less than the originator. That's huge for healthcare budgets. What's the catch? Biosimilars are not generics — they're...

0 Comments 0 Shares 6 Views 0 Reviews